Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAHI-SC3
- Development stage
- Discontinued
- Lead developer
- ImmunityBio
- Modality
- Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
AAHI-SC3 is a self-amplifying RNA (saRNA) vaccine candidate developed by the Access to Advanced Health Institute (AAHI) in collaboration with ImmunityBio for the prevention of COVID-19. Unlike conventional mRNA vaccines, saRNA vaccines incorporate genetic machinery derived from alphaviruses that allows the RNA to replicate itself once inside the host cell. This self-amplification process potentially enables lower dosing requirements and more durable immune responses compared to standard mRNA platforms. AAHI-SC3 is formulated using AAHI's proprietary Lipid Inorganic Nanoparticle (LION) delivery system, which is designed to enhance the stability of the RNA and act as an adjuvant to boost immunogenicity. The vaccine is currently being evaluated as a booster in the THEMBA II Phase 1/2 clinical trial in South Africa, targeting adults who have been previously vaccinated or infected with SARS-CoV-2.
- Other names
- saRNA COVID-19 booster vaccineTHEMBA II vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on AAHI-SC3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAHI-SC3.